Adjuvant Pembrolizumab Significantly Improves DFS in Renal Cell Carcinoma

Pembrolizumab was associated with a 32% reduction in the risk of disease recurrence or death compared with placebo as an adjuvant treatment for patients with clear cell renal cell carcinoma.

Read the full article here

Related Articles